PRCT · PROCEPT BioRobotics Corp
Market Cap
$1.19B
Shares
57.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.83
Open$20.76
Day$20.42–20.97
52W close$16.69–40.68
Avg vol 30d1.5M
Short int7.7M · 13.5% float · 3.5d
Short vol48%
Last earningsAug 4, 2026
DataSep 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
+2%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−18%
trailing
YTD return
−34%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $26 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$469.8K over 90 days · 75% sells
Short interest
Rising
13.45% of float · ▲ +8.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
257 holders — mid 3-yr range
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
Gross margin
64%
expanding
EPS growth
+2%
Y/Y
Free cash flow
$-58.3M
Balance sheet
$234.9M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Revenue
· full year 2026
Maintained
$390M – $410M
Apr 29, 2026
$390M – $410M
changed to
Aug 4, 2026
$390M – $410M
prior FY $308.05M
midpoint +29.8% Y/Y
Gross margin
· full year 2026
Maintained
65%
Jun 30, 2026
65%
changed to
Aug 4, 2026
65%
Prior guidance
period ended
· from the 8-K filed Feb 25, 2026
Total revenue
· first quarter of 2026
$79M – $82M
Guided vs delivered
· last 5 settled
Revenue for the full year 2025
full year 2025
guided $325.5M
$308.05M
Miss −5.4%
Revenue
first quarter of 2025
guided $65.5M
$69.16M
Beat +5.6%
Total revenue
full year 2024
guided $210M
$224.5M
Beat +6.9%
Total revenue
full-year 2023
guided $131M
$136.19M
Beat +4.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
+2%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $26 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$469.8K over 90 days · 75% sells
Short interest
Rising
13.45% of float · ▲ +8.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
257 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $17
Now $21 · 17%
Range high $41
vs 200-day avg -21%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $11.3M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss -26.86M
+1.99M Depreciation and amortization expense
+14.53M Stock-based compensation expense
-992K Interest (income) and interest expense, net
= Adjusted EBITDA -11.33M
|
|||
| Handpiece average selling price | $3,550 | Q2 2026 | — |
|
|
|||
| U.S. average selling prices for new HYDROS systems | $495,000 | Q2 2026 | — |
|
|
|||
| U.S. handpieces sold as percent of U.S. procedures | 98% | Q2 2026 | — |
|
|
|||
| U.S. Hydros systems sold | 65 | Q2 2026 | — |
|
|
|||
| U.S. install base | 765 | Q2 2026 | — |
|
|
|||
| U.S. procedures | 13,100 | Q2 2026 | — |
|
|
|||
| New systems sold | 65 | Q4 2025 | — |
| U.S. handpieces sold | 9,400 | Q4 2025 | — |
| U.S. Systems placed | 213K | FY 25 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRCT
this stock
PROCEPT BioRobotics Corp
|
$1.19B | -33.8% | +37.2% | — | 13.5% |
|
ABT
Abbott Laboratories
|
$195.90B | -10.2% | +5.7% | 31.5 | 1.2% |
|
SYK
Stryker Corp
|
$127.12B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$115.17B | -5.0% | +8.4% | 24.1 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -50.9% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRCT | -3.9% | +11.9% | -17.5% | +11.9% | -33.8% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.4% | +8.9% | -31.0% | +8.9% | -46.6% |
Key facts
CIK
1588978
CUSIP
74276L105
13F (30d)
216 filings
210 filers
Visit website
Investor relations